PFS
FIG 1. · Panel A
Panel A 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Krzysztof Giannopoulos, Martin Šimkovič, Anders Österborg, Luca Laurenti, Patricia A Walker, Stephen S Opat, Hanna Ciepluch, Richard Greil, Merit Hanna, Monica Tani, Marek Trněný, Danielle Brander, Ian W Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Sophie de Guibert, Gayane Tumyan, Kamel Laribi, José A García-Marco, Jian-Yong Li, Tian Tian, Yu Liu, Roman Korolkiewicz, Andy Szeto, Constantine S Tam, Wojciech Jurczak
J Clin Oncol 43(7) 780-787
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.2 months) and subsequent analysis (43.7 months) found superior progression-free survival (PFS; the primary end point) in patients who received zanubrutinib compared with BR. At a median follow-up of 61.2 months, median PFS was not reached in zanubrutinib-treated patients; median PFS was 44.1 months in BR-treated patients (hazard ratio [HR], 0.29; one-sided P = .0001). Prolonged PFS was seen with zanubrutinib versus BR in patients with mutated immunoglobulin heavy-chain variable region (IGHV) genes (HR, 0.40; one-sided P = .0003) and unmutated IGHV genes (HR, 0.21 [95% CI, 0.14 to 0.33]; one-sided P < .0001). Median overall survival (OS) was not reached in either treatment arm; estimated 60-month OS rates were 85.8% and 85.0% in zanubrutinib- and BR-treated patients, respectively. No new safety signals were detected. Adverse events were as expected with zanubrutinib; rate of atrial fibrillation was 7.1%. At a median follow-up of 61.2 months, the results supported the initial SEQUOIA findings and suggested that zanubrutinib was a favorable treatment option for untreated patients with CLL/SLL.
1 个 Figure · 5 个 KM 面板
FIG 1. PFS and OS in zanubrutinib- and BR-treated patients (ITT). HRs and 95% CIs were based on a stratified Cox regression model with the BR arm as the reference group; stratification factors were age ( < 65 years v ≥65 years), Binet stage (C v A or B), and IGHV gene mutational status (mutated v unmutated). All P values were one-sided and descriptive. (A) PFS in the overall population; (B) PFS in patients with mutated and unmutated IGHV genes; (C) PFS in the overall population adjusted for COVID-19; (D) OS in the overall population; (E) OS in the overall population adjusted for COVID-19. BR, bendamustine plus rituximab; HR, hazard ratio; IGHV, immunoglobulin heavy-chain variable region; ITT, intention-to-treat; OS, overall survival; PFS, progression-free survival.
FIG 1. · Panel A
Panel A 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 1. · Panel B
Panel B 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 1. · Panel C
Panel C 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 1. · Panel D
Panel D 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 1. · Panel E
Panel E 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。